Market Analysis and Insights: Global Anti-Obesity Prescription Drugs Market
Due to the pandemic of COVID-19, the global Anti-Obesity Prescription Drugs Market size is estimated to be worth US$ million in 2022 and is expected to reach the size of US$ million by 2028 growing at a CAGR of % during the forecast period. Fully considering the economic change by this health crisis, Pediatric accounted for % of the global Anti-Obesity Prescription Drugs Market in 2021 and is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Hospitals Pharmacies segment is altered to a % CAGR throughout this forecast period.
China Anti-Obesity Prescription Drugs Market size is valued at US$ million in 2021, while the US and Europe Anti-Obesity Prescription Drugs Market are US$ million and US$ million, respectively. The share of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China’s share will reach % in 2028, trailing a CAGR of % through the forecast period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Anti-Obesity Prescription Drugs Market landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Anti-Obesity Prescription Drugs Market include F Hoffmann La Roche Ltd, Orexigen Therapeutics, Novo Nordisk A/s, Arena Pharmaceuticals, Glaxosmithkline, Vivus, Boehringer Ingelheim, Alizyme, , etc. In 2021, the global top five players have a share of approximately % in terms of revenue.
In terms of the production, this report researches the Anti-Obesity Prescription Drugs Market capacity, production, growth rate, market share by manufacturers and by region (region level and country level), from 2017 to 2022, and forecast to 2028.
In terms of the sales, this report focuses on the sales of Anti-Obesity Prescription Drugs Market by region (region level and country level), by company, by Type and by Application from 2017 to 2022 and forecast to 2028.
The authors of this research report have explored the key segments: Type and Application. The report offers an in-depth breakdown of type and application segments and their sub-segments. The lucrativeness and growth potential have been looked into by the industry experts in this report. This section of the report also provides sales and revenue forecast data by type and application segments based on sales, price, and revenue for the period 2017-2028. The specialists, to broaden the understanding of the users, have done value chain and raw material analysis in this section.
Anti-Obesity Prescription Drugs market is segmented by Type and
by Application. Players, stakeholders, and other participants in
the global Anti-Obesity Prescription Drugs market will be able to
gain the upper hand as they use the report as a powerful resource.
The segmental analysis focuses on sales, revenue and forecast by
Type and by Application for the period 2017-2028.
Segment by Type
Segment by Application
F Hoffmann La Roche Ltd
Novo Nordisk A/s
Middle East & Africa